The regulatory landscape for extracellular vesicle therapies: Australian context and future directions

Abstract

Extracellular vesicles (EVs) are emerging as promising tools for regenerative medicine and drug delivery, offering unique therapeutic advantages. However, their clinical translation - in Australia and globally - faces persistent challenges. These are commonly framed as technical issues stemming from inherent EV variability and the absence of standardized potency assays. While no EV-based therapeutic has yet received full market approval from any major regulatory agency, this Perspective argues that the barriers to translation are not solely technical but reflect limitations within current regulatory frameworks. In Australia, the Therapeutic Goods Administration (TGA) requires biological products to be included on the Australian Register of Therapeutic Goods (ARTG) before supply to market. However, several alternative regulatory pathways exist that can facilitate clinical access to “unapproved” products. Through analysis of these pathways, and comparison with international approaches, this Perspective highlights how regulatory inflexibility may be as significant a barrier to translating EV medicines as the technical difficulties themselves. Drawing on insights from governmental inquiries into the approval and subsidization of emerging medicines, the Perspective calls for reform of Australia’s regulatory systems - including development of EV-specific guidance and policy that introduces adaptive assessment pathways - to better support the safe and timely integration of novel biotechnologies.

Keywords

Extracellular vesicles / Australian therapeutic goods regulation / precision medicine variability / innovative medicines regulation

References

[1] Du S,Xie A.Extracellular vesicles: a rising star for therapeutics and drug delivery.J Nanobiotechnology2023;21:231 PMCID:PMC10360328

[2] Kumar MA,Sadida HQ.Extracellular vesicles as tools and targets in therapy for diseases.Signal Transduct Target Ther2024;9:27 PMCID:PMC10838959

[3] Jay SM.Addressing barriers to clinical translation of extracellular vesicle therapeutics.Mol Ther2025;33:1879-80 PMCID:PMC12126779

[4] Mizenko RR,Bozkurt BT.A critical systematic review of extracellular vesicle clinical trials.J Extracell Vesicles2024;13:e12510 PMCID:PMC11428870

[5] Moghassemi S,Sousa MJ.Extracellular vesicles in nanomedicine and regenerative medicine: a review over the last decade.Bioact Mater2024;36:126-56 PMCID:PMC10915394

[6] Giebel B.A milestone for the therapeutic EV field: FDA approves Ryoncil, an allogeneic bone marrow-derived mesenchymal stromal cell therapy.Extracell Vesicles Circ Nucl Acids2025;6:183-90 PMCID:PMC11977348

[7] Fujita M,Ikka T.The urgent need for clear and concise regulations on exosome-based interventions.Stem Cell Reports2024;19:1517-9 PMCID:PMC11589178

[8] Therapeutic Goods Administration (TGA). Australian Register of Therapeutic Goods (ARTG). Available from: https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg. [Last accessed on 27 Feb 2026]

[9] House of Representatives Standing Committee on Health, Aged Care and Sport Report. The New Frontier - Delivering better health for all Australians: inquiry into approval processes for new drugs and novel medical technologies in Australia. Available from: https://www.aph.gov.au/Parliamentary_Business/Committees/House/Former_Committees/Health_Aged_Care_and_Sport/Newdrugs/Report. [Last accessed on 25 Feb 2026]

[10] Department of Health and Aged Care. Health technology assessments. Available from: https://www.health.gov.au/topics/health-technologies-and-digital-health/health-technology-assessments. [Last accessed on 25 Feb 2026]

[11] TGA Online Database. Australian Register of Therapeutic Goods (ARTG). Available from: https://www.tga.gov.au/resources/artg. [Last accessed on 25 Feb 2026]

[12] Ghodasara A,Wolfram J,Popat A.Clinical Translation of Extracellular Vesicles.Adv Healthc Mater2023;12:e2301010

[13] Therapeutic Goods Act 1989 (Cth) Part 3-2A Division 4. Available from: https://www.legislation.gov.au/C2004A03952/latest. [Last accessed on 25 Feb 2026]

[14] Mesoblast Limited ASX Announcement. Mesoblast receives complete response from U.S. Food and Drug Administration for biologics license application for steroid-refractory acute graft versus host disease in children. Available from: https://investorsmedia.mesoblast.com/static-files/422cd6da-a0b9-49cf-a177-7fd106f111f2. [Last accessed on 25 Feb 2026]

[15] Welsh JA, Goberdhan DCI, O’Driscoll L, et al; MISEV Consortium. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles. 2024;13:e12404. PMCID:PMC10850029

[16] Therapeutic Goods Act 1989 (Cth) section 32AA. Available from: https://www.legislation.gov.au/C2004A03952/latest. [Last accessed on 25 Feb 2026]

[17] TGA. Classification of biologicals: Australian Regulatory Guidelines for Biologicals (ARGB). Available from: https://www.tga.gov.au/sites/default/files/classification-biologicals.pdf. [Last accessed on 25 Feb 2026]

[18] Phan TH,Rudge C.Made by cells for cells - extracellular vesicles as next-generation mainstream medicines.J Cell Sci2022;135:jcs259166

[19] Therapeutic Goods (Biologicals-Information that Must Accompany Application for Inclusion in Register) Determination July 2018 (Cth). Available from: https://www.legislation.gov.au/F2018L01078/latest. [Last accessed on 25 Feb 2026]

[20] TGA. Dossier requirements for Class 2, 3 and 4 biologicals. Australian Regulatory Guidelines for Biologicals (ARGB). Available from: https://www.tga.gov.au/resources/guidance/dossier-requirements-class-2-3-and-4-biologicals. [Last accessed on 25 Feb 2026]

[21] TGA. Special Access Scheme (SAS): Guidance for health practitioners accessing unapproved therapeutic goods. Available from: https://www.tga.gov.au/resources/guidance/special-access-scheme-sas-guidance-health-practitioners-accessing-unapproved-therapeutic-goods. [Last accessed on 25 Feb 2026]

[22] Therapeutic Goods Regulations 1990 (Cth) r 12A(5). Available from: https://www.legislation.gov.au/F1996B00406/latest. [Last accessed on 25 Feb 2026]

[23] Therapeutic Goods Regulations 1990 (Cth) r 12A(2)-(3). Available from: https://www.legislation.gov.au/F1996B00406/latest. [Last accessed on 25 Feb 2026]

[24] TGA Online Database. Special Access Scheme (SAS) Category C lists. Available from: https://www.tga.gov.au/products/unapproved-therapeutic-goods/prescribe-unapproved-therapeutic-good-health-practitioners/lists-products-established-history-use/special-access-scheme-sas-category-c-lists#biologicals. [Last accessed on 25 Feb 2026]

[25] TGA. Access unapproved products (consumers). Available from: https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-unapproved-products-consumers. [Last accessed on 25 Feb 2026]

[26] TGA. Authorised Prescriber Scheme: Guidance for medical practitioners, Human Research Ethics Committees, specialist colleges and sponsors. Available from: https://www.tga.gov.au/sites/default/files/2024-03/authorised-prescriber-scheme-guidance.docx. [Last accessed on 25 Feb 2026]

[27] McClelland R, Rudge C. The medicalisation of psychedelic drugs in Australia: regulatory implications of a novel treatment. Melb Univ Law Rev. 2025;48:733. Available from: https://law.unimelb.edu.au/__data/assets/pdf_file/0005/5478719/McClelland-and-Rudge-MULR-483-733.pdf. [Last accessed on 27 Feb 2026]

[28] Therapeutic Goods Act 1989 (Cth) section 7AA. Available from: https://www.legislation.gov.au/C2004A03952/latest. [Last accessed on 25 Feb 2026]

[29] Therapeutic Goods Act 1989 (Cth) section 18. Available from: https://www.legislation.gov.au/C2004A03952/latest. [Last accessed on 25 Feb 2026]

[30] Therapeutic Goods (Excluded Goods) Determination 2018 (Cth) section 6. Available from: https://www.legislation.gov.au/F2018L01350/latest. [Last accessed on 25 Feb 2026]

[31] TGA. Determining if a biological product is for homologous use. Available from: https://www.tga.gov.au/resources/guidance/determining-if-biological-product-homologous-use. [Last accessed on 25 Feb 2026]

[32] TGA. Understanding the minimal manipulation method of preparation for biologicals. Available from: https://www.tga.gov.au/resources/guidance/understanding-minimal-manipulation-method-preparation-biologicals. [Last accessed on 25 Feb 2026]

[33] Liu YJ.A review of the regulatory mechanisms of extracellular vesicles-mediated intercellular communication.Cell Commun Signal2023;21:77 PMCID:PMC10100201

[34] Bahmani L.Different sourced extracellular vesicles and their potential applications in clinical treatments.Cells2022;11:1989 PMCID:PMC9265969

[35] Kim HI,Zhu Y,Han Y.Recent advances in extracellular vesicles for therapeutic cargo delivery.Exp Mol Med2024;56:836-49 PMCID:PMC11059217

[36] Tam S,Morrone CD.The complexity of extracellular vesicles: Bridging the gap between cellular communication and neuropathology.J Neurochem2024;168:2391-422

[37] Verma N.Navigating the global regulatory landscape for exosome-based therapeutics: challenges, strategies, and future directions.Pharmaceutics2025;17:990 PMCID:PMC12389065

[38] Greening DW,Rai A,Chen M.Clinical relevance of extracellular vesicles in cancer - therapeutic and diagnostic potential.Nat Rev Clin Oncol2025;22:924-52

[39] Rudge C,Kerridge I,Stewart C.A new priority pathway for biologicals in Australia: contextualising and evaluating the proposed reforms.J Law Med2022;29:677-99

[40] Van Delen M, Derdelinckx J, Wouters K, Nelissen I, Cools N. A systematic review and meta-analysis of clinical trials assessing safety and efficacy of human extracellular vesicle-based therapy.J Extracell Vesicles2024;13:e12458 PMCID:PMC11220457

[41] Australian Government. Australian Government response to the Standing Committee on Health, Aged Care and Sport report: The New Frontier - Delivering better health for all Australians. Available from: https://www.health.gov.au/sites/default/files/2023-11/inquiry-into-approval-processes-for-new-drugs-and-novel-medical-technologies-in-australia.pdf. [Last accessed on 25 Feb 2026]

[42] Health Technology Assessment Policy and Methods Review. Accelerating access to the best medicines for Australians now and into the future. Available from: https://www.health.gov.au/sites/default/files/2024-09/health-technology-assessment-policy-and-methods-review-final-report_0.pdf. [Last accessed on 25 Feb 2026]

[43] Health Technology Assessment Policy and Methods Review. Emerging health technologies. Available from: https://health.gov.au/sites/default/files/2024-07/hta-policy-and-methods-review-emerging-health-technologies.pdf. [Last accessed on 25 Feb 2026]